Drug combo paves way for Kidney-Saving surgery in tough cancer cases
NCT ID NCT06138496
Summary
This study tested whether giving a combination of two drugs (cadonilimab and lenvatinib) before surgery could help patients with high-risk kidney cancer successfully undergo a kidney-sparing operation. The goal was to shrink tumors enough to make a complex, kidney-preserving surgery possible and safe. The trial involved 39 adults with localized kidney cancer where surgery was particularly difficult.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Other (Non U.s.), 0755, China
Conditions
Explore the condition pages connected to this study.